Exicure, Inc. (XCUR:NASDAQ) Annual Reports & Investor Relations Material

Overview

Chicago-based Exicure Inc., an early-phase biotech firm, is working on developing nucleic acid therapies using ribonucleic acid to target validated goals. Their preclinical drug candidate features SCN9A, currently in preclinical trials intended for the treatment of chronic pain. The company also focuses on developing immuno-oncology therapeutics reliant on their proprietary SNA technology. Founded in 2011, Exicure Inc. continues to evolve and grow within the biotechnology industry with their promising developments in nucleic acid therapy.

Annual Reports

Frequently Asked Questions

What is Exicure, Inc.'s ticker?

Exicure, Inc.'s ticker is XCUR

What exchange is Exicure, Inc. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Exicure, Inc.'s headquarters?

They are based in Chicago, Illinois

How many employees does Exicure, Inc. have?

There are 11-50 employees working at Exicure, Inc.

What is Exicure, Inc.'s website?

It is https://exicuretx.com/

What type of sector is Exicure, Inc.?

Exicure, Inc. is in the Healthcare sector

What type of industry is Exicure, Inc.?

Exicure, Inc. is in the Biotechnology industry

Who are Exicure, Inc.'s peers and competitors?

The following five companies are Exicure, Inc.'s industry peers:

- Aytu Biopharma

- Cyclerion Therapeutics, Inc.

- Vertex Pharmaceuticals

- Cancer Genetics, Inc.

- Acer Therapeutics Inc.